Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

PubWeight™: 40.72‹?› | Rank: Top 0.01% | All-Time Top 1000

🔗 View Article (PMID 7968073)

Published in Lancet on November 19, 1994

Associated clinical trials:

French Registry of Acute Coronary Syndrome (Fast-MI) | NCT00673036

C2 -CORVUS Cholesterol-Control (C2) Controlled Targets for High Vascular Risk Patients Using Effective Statins (CORVUS) (C2 -CORVUS) | NCT00921752

Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease | NCT00552747

Articles citing this

(truncated to the top 100)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 16.52

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) BMJ (1998) 7.48

Performance indicators for primary care groups: an evidence based approach. BMJ (1998) 6.97

Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ (1998) 6.79

Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ (2001) 6.32

Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med (2013) 5.87

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med (2000) 5.72

Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov (2012) 5.55

Risk factor thresholds: their existence under scrutiny. BMJ (2002) 5.55

Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ (2009) 5.14

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. BMJ (1999) 4.94

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet (2010) 4.23

Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. BMJ (1998) 4.21

Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart (1999) 4.04

Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med (2008) 3.99

Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. BMJ (1998) 3.81

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ (2005) 3.80

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ (2005) 3.72

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ (2006) 3.68

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 3.50

Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol (2014) 3.45

Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. BMJ (1998) 3.40

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ (2009) 3.39

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35

Dietary fat intake and prevention of cardiovascular disease: systematic review. BMJ (2001) 3.29

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23

A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ (1999) 3.23

Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06

Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ (2005) 3.00

The Treatment of Disorders of Lipid Metabolism. Dtsch Arztebl Int (2016) 2.91

Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ (2000) 2.90

Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ (2009) 2.88

Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (2002) 2.83

Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ (2005) 2.75

Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68

What is the optimal age for starting lipid lowering treatment? A mathematical model. BMJ (2000) 2.65

Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs (2008) 2.62

Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ (1998) 2.59

Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ (2000) 2.57

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ (2002) 2.55

Improving care for patients with acute coronary syndromes: initial results from the National Audit of Myocardial Infarction Project (MINAP). Heart (2004) 2.38

A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ (2007) 2.35

Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. Am J Hum Genet (2014) 2.33

Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32

Automating complex guidelines for chronic disease: lessons learned. J Am Med Inform Assoc (2003) 2.30

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (2016) 2.25

Evidence of sample use among new users of statins: implications for pharmacoepidemiology. Med Care (2014) 2.22

An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ (2010) 2.22

Medicalisation, limits to medicine, or never enough money to go around? BMJ (2002) 2.21

Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21

Time trend analysis and variations in prescribing lipid lowering drugs in general practice. BMJ (1998) 2.21

Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart (2003) 2.20

Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19

Isoprenoids as mediators of the biological effects of statins. J Clin Invest (2002) 2.19

Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol (2004) 2.18

Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet (2003) 2.18

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol (2008) 2.13

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13

Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke (2005) 2.13

From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ (1998) 2.12

Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol (2011) 2.11

Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels (2011) 2.07

Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ (1998) 2.07

Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med (2010) 2.06

Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg (2013) 2.05

Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2006) 2.04

Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med (2004) 2.01

A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One (2006) 2.01

Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart (2002) 1.98

Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol (2010) 1.91

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control Clin Trials (2004) 1.90

Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol (2005) 1.89

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J (2015) 1.83

Rapid assessment of chest pain. BMJ (2001) 1.82

A qualitative study of evidence in primary care: what the practitioners are saying. CMAJ (2002) 1.80

Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: prospective cohort study. BMJ (2011) 1.80

Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med (2011) 1.77

Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev (2012) 1.76

Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol (2012) 1.76

Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV (2015) 1.75

Use of statins in general practices, 1996-8: cross sectional study. BMJ (2000) 1.73

Why training and specialization is needed for peer review: a case study of peer review for randomized controlled trials. BMC Med (2014) 1.71

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc Diabetol (2005) 1.71

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis (2011) 1.70

Effects of n-3 fatty acids on major cardiovascular events in statin users and non-users with a history of myocardial infarction. Eur Heart J (2012) 1.67

Long-term statin use and psychological well-being. J Am Coll Cardiol (2003) 1.66

Use of Coronary Computed Tomographic Angiography to Guide Management of Patients With Coronary Disease. J Am Coll Cardiol (2016) 1.66

Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med (1999) 1.64

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol (1999) 1.64

Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ (2000) 1.64

Survival in treated hypertension: follow up study after two decades. BMJ (1998) 1.64

Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ (2003) 1.63